valdecoxib


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to valdecoxib: rofecoxib, Parecoxib

valdecoxib

/val·de·cox·ib/ (val″dĕ-kok´sib) a nonsteroidal antiinflammatory drug of the COX-2 inhibitors group, used for the treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea.

valdecoxib

a nonsteroidal antiinflammatory used to treat acute and chronic rheumatoid arthritis, osteoarthritis, and primary dysmenorrhea.

Bextra

A next-generation NSAID Cox-2 inhibitor used for managing pain due to osteoarthritis, rheumatoid arthritis, dysmenorrhea, etc.
 
Adverse effects
Rarely, serious skin and hypersensitivity reactions (e.g., Stevens Johnson syndrome); toxic epidermal necrolysis; exfoliative dermatitis; erythema multiforme, possibly requiring hospitalisation; Bextra is contraindicated with sulfa drugs.

valdecoxib

See Bextra®.

valdecoxib

A COX-2 inhibitor drug used to treat OSTEOARTHRITIS, RHEUMATOID ARTHRITIS and DYSMENORRHOEA. A brand name is Bextra. In late 2004 the drug was shown to have cardiotoxic properties similar to those of rofecoxib and it was recommended that the drug should be withdrawn.
References in periodicals archive ?
Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea.
To this 1 ml of Valdecoxib (2 [micro]g/ml) was added and then the mixture was sonicated for 20 min and then filtered.
Some of the most selective drugs, like celecoxib and valdecoxib, are on the lower side," Dr.
In early April 2005, the FDA asked the manufacturer (Pfizer) to withdraw valdecoxib (Bextra) from the market because the overall risk versus benefit profile for the drug was found to be unfavorable.
I would like more investigations into Valdecoxib to take place.
There is no available alternative for migraine sufferers yet, though Pfizer's valdecoxib is currently awaiting approval for this indication.
Valdecoxib for postoperative pain management after cesarean delivery: a randomized, double-blind, placebo-controlled study.
Both valdecoxib in its clinical exposure and celecoxib in ankylosing spondylitis show similar results.
There was no increased risk for those using celecoxib or valdecoxib.
One thing is for certain: A simple, safe, analgesic patch would be welcome news for patients and physicians beleaguered by the withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) and the addition of a black box warning on celecoxib.
What's more, later in 2004, FDA issued a warning about heart risks linked to a related drug, valdecoxib (Bextra), and manufacturer Pfizer stopped consumer advertising of a third such drug, celecoxib (Celebrex), because of worrisome new cardiovascular findrags.
parecoxib, the injectable prodrug of valdecoxib, for treatment of acute